Feb 24, 2026 09:04AM
Feb 24, 2026 05:40AM
Feb 23, 2026 12:32PM
Feb 23, 2026 12:17PM
Feb 23, 2026 07:00AM
Jan 13, 2026 04:52AM
Jan 8, 2026 03:37AM Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight
Jan 5, 2026 06:40AM
Jan 2, 2026 08:53AM
Jan 2, 2026 06:23AM
Dec 31, 2025 01:54PM
Dec 31, 2025 01:20PM
Dec 31, 2025 01:19PM
Dec 31, 2025 12:42PM Axsome Therapeutics (AXSM) PT Raised to $220 at Oppenheimer
Dec 31, 2025 08:25AM
Dec 31, 2025 08:24AM
Dec 31, 2025 07:00AM
Dec 31, 2025 07:00AM
Dec 31, 2025 06:55AM
Dec 31, 2025 06:55AM
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Dec 16, 2024 07:03AM
Nov 26, 2024 07:00AM
Nov 26, 2024 07:00AM
Nov 12, 2024 07:00AM
Sep 5, 2024 06:48AM
Sep 4, 2024 07:01AM
Sep 4, 2024 07:00AM Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
Apr 30, 2024 09:00PM
Apr 17, 2024 09:00PM
Apr 12, 2024 02:30AM
Apr 3, 2024 09:00PM
Mar 25, 2024 09:00PM
Mar 25, 2024 06:31AM
Mar 25, 2024 06:30AM Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Aug 19, 2022 10:39AM
Jul 4, 2022 09:00PM
Jun 29, 2022 09:00PM
Jun 24, 2022 09:00PM
Jun 19, 2022 09:00PM
Jun 13, 2022 09:00PM
Jun 8, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Upstart, Oscar, Axsome, and Humbl and Encourages Investors to Contact the Firm
Jun 3, 2022 09:00PM
Jun 2, 2022 08:10AM
May 29, 2022 09:00PM
May 23, 2022 09:00PM
May 18, 2022 09:00PM
Apr 25, 2022 08:29AM
Mar 1, 2022 09:21AM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Mar 1, 2022 07:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All